Business

Adia Nutrition Inc. Delivers Explosive Third Quarter Growth: Revenue Surges Over 100% from Prior Quarter, with Remarkable Profit Margin Exceeding 20%

Winter Park, Florida--(Newsfile Corp. - October 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a trailblazer in umbilical cord stem cells and exosome sales and therapies, today announced phenomenal preliminary financial results for the third quarter ended September 30, 2025. The company achieved a monumental revenue increase of more than 100% compared to the second quarter, while posting an extraordinary profit margin exceeding 20% for the quarter. This blockbuster performance cements Adia...

articleAdia Nutrition, Inc.October 8, 20253/company/adia-nutrition-inc/news/adia-nutrition-inc-delivers-explosive-third-quarter-growth-revenue-surges-over-100percent-from-prior-quarter-with-remarkable-profit-margin-exceeding-20percent
Adia Nutrition Inc. Delivers Explosive Third Quarter Growth: Revenue Surges Over 100% from Prior Quarter, with Remarkable Profit Margin Exceeding 20%

About this update from Adia Nutrition, Inc.

[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - October 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a trailblazer in umbilical cord stem cells and exosome sales and therapies, today announced phenomenal preliminary financial results for the third quarter ended September 30, 2025. The company achieved a monumental revenue increase of more than 100% compared to the second quarter, while posting an extraordinary profit margin exceeding 20% for the quarter. This blockbuster performance cements Adia Nutrition's leadership in the thriving regenerative medicine industry, driven by soaring demand for its innovative, science-driven stem cell and exosome therapies.","length":661,"tagName":"p"},{"type":"text","content":""This third quarter marks a historic leap forward for Adia Nutrition," said CEO Larry Powalisz. "Doubling our revenue in a single quarter while achieving such a robust profit margin is a powerful reflection of our team's dedication, our cutting-edge therapeutic portfolio, and the trust of our rapidly expanding customer base. We're not just growing, we're redefining what's possible in the regenerative medicine space."","length":456,"tagName":"p"},{"type":"text","content":"Key highlights from the preliminary third quarter results include:","length":66,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue Surge: Revenue grew by over 100% from the second quarter, fueled by skyrocketing sales of umbilical cord stem cells and exosomes across clinical partnerships, direct-to-consumer channels, and national market expansion.","length":226,"tagName":"p"}]},{"val":[{"type":"text","content":"Profit Triumph: A profit margin exceeding 20%, showcasing operational efficiency, strategic investments, and the strength of high-margin therapeutic offerings resonating with patients and healthcare providers.","length":209,"tagName":"p"}]},{"val":[{"type":"text","content":"Unstoppable Momentum: These results build on Adia Nutrition's year-to-date success, positioning the company for record-breaking annual growth and enhanced shareholder value.","length":177,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":612,"olType":false},{"type":"text","content":"The full third quarter financial report, including reviewed statements and detailed metrics, will be released and posted ...

More updates from Adia Nutrition, Inc.

Adia Nutrition Inc.Adia Nutritionprofit marginregenerative medicinestem cell therapies